Synthesis of Cationic Silver Nanoparticles with Highly Potent Properties against Oral Pathogens and Their Biofilms
Source abstract
Abstract
Abstract Dental caries is a major disease associated with the proliferation of acidogenic bacterial species such as Streptococcus mutans that are part of the commensal microbiota of the mouth. Silver nanoparticles (AgNPs) are attractive antibacterial agents as they target multiple sites in bacteria which reduces antimicrobial resistance. In this study, we synthesised stable, highly positively charged AgNPs capped with branched PEI (BPEI‐AgNPs) and characterized them using UV–vis absorption, transmission electron microscopy (TEM), the size of which were approximately 7.5 nm. The antibacterial activity and anti‐biofilm capacity of BPEI‐AgNPs was investigated against cariogenic bacteria. Our results demonstrated that BPEI‐AgNPs are potent clinical oral antiseptics. The cytotoxicity of the BPEI‐AgNPs was also studied against two mammalian cell lines. The results indicated that BPEI‐AgNPs were non‐cytotoxic and were safer than commercially used dental antiseptics. We conclude that the BPEI‐AgNPs are safe for oral clinical application and are an effective oral antimicrobial agent.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Oral microbiology and periodontitis research · Scientific and Engineering Research Topics · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Adelaide Dental School University of Adelaide Adelaide SA 5000 Australia
Department of pharmacology, School of biomedicine University of Adelaide Adelaide SA 5000 Australia
Academic Unit of STEM University of South Australia Mawson Lakes SA 5095 Australia
College of Medicine and Public Health Flinders University Bedford Park SA 5042 Australia
Funding
Australian Dental Research Foundation · University of South Australia · National Health and Medical Research Council
References (93)
Show source-provided references
1.
2. 10.1021/acs.jmedchem.8b0143910.1021/acs.jmedchem.8b01439 ↗
3. NIH National Institute of Health2002.
4. 10.1007/978-3-540-75418-3_310.1007/978-3-540-75418-3_3 ↗
5.
6. 10.1038/nrmicro241510.1038/nrmicro2415 ↗
7. 10.1016/S0966-842X(01)02012-110.1016/S0966-842X(01)02012-1 ↗
8.
9. 10.2217/fmb.12.7610.2217/fmb.12.76 ↗
10. 10.1111/joim.1200410.1111/joim.12004 ↗
11. 10.1128/JB.00542-1010.1128/JB.00542-10 ↗
12. 10.1177/0022034592071005060110.1177/00220345920710050601 ↗
13. 10.3389/fmicb.2021.65647110.3389/fmicb.2021.656471 ↗
14.
15. 10.3390/ijms1704050910.3390/ijms17040509 ↗
16. 10.1186/s12951-017-0308-z10.1186/s12951-017-0308-z ↗
17.
18. 10.1007/s10856-013-4894-510.1007/s10856-013-4894-5 ↗
19. 10.1016/j.matlet.2009.09.01810.1016/j.matlet.2009.09.018 ↗
20.
21. 10.1093/jac/dkl18110.1093/jac/dkl181 ↗
22. 10.1111/j.1365-2672.2012.05253.x10.1111/j.1365-2672.2012.05253.x ↗
23. 10.1111/j.1600-0757.1997.tb00105.x10.1111/j.1600-0757.1997.tb00105.x ↗
24. James P. · Cochrane Database Syst. Rev. · 2017
25. 10.4317/jced.5499510.4317/jced.54995 ↗
26.
27. 10.1016/j.msec.2018.03.03510.1016/j.msec.2018.03.035 ↗
28. 10.1016/j.jphotobiol.2019.11164210.1016/j.jphotobiol.2019.111642 ↗
29.
30. 10.1016/j.jdent.2018.12.00110.1016/j.jdent.2018.12.001 ↗
31. 10.1039/C9NA00017H10.1039/C9NA00017H ↗
32. 10.1016/j.dental.2007.04.01510.1016/j.dental.2007.04.015 ↗
33. 10.1007/s10856-010-4102-910.1007/s10856-010-4102-9 ↗
34. 10.1177/0022034589068006060110.1177/00220345890680060601 ↗
35. 10.1016/j.colsurfb.2016.03.00710.1016/j.colsurfb.2016.03.007 ↗
36.
37. 10.1016/j.colsurfb.2012.07.03910.1016/j.colsurfb.2012.07.039 ↗
38. Haidari H. · ACS Appl. Mater. Interfaces · 2021
39. 10.1021/acsami.0c0941410.1021/acsami.0c09414 ↗
40. 10.2341/19-109-L10.2341/19-109-L ↗
41.
42. 10.3389/fmicb.2016.0183110.3389/fmicb.2016.01831 ↗
43. 10.1007/s11356-015-5668-z10.1007/s11356-015-5668-z ↗
44. 10.3390/nano604007410.3390/nano6040074 ↗
45.
46. 10.1186/1477-3155-12-510.1186/1477-3155-12-5 ↗
47. 10.1039/C3RA44507K10.1039/C3RA44507K ↗
48. 10.1155/2015/72065410.1155/2015/720654 ↗
49. 10.1039/C6RA00194G10.1039/C6RA00194G ↗
50.
51. 10.1016/S1525-0016(02)00053-910.1016/S1525-0016(02)00053-9 ↗
52. 10.1023/A:101486190047810.1023/A:1014861900478 ↗
53.
54. 10.1016/j.biomaterials.2011.07.04710.1016/j.biomaterials.2011.07.047 ↗
55. Kafil V. · Bioimpacts. · 2011 · 1 · 23
56. 10.1021/ma00173a00910.1021/ma00173a009 ↗
57. 10.1021/la701236v10.1021/la701236v ↗
58.
59. 10.1021/jp075436g10.1021/jp075436g ↗
60. 10.1016/j.msec.2012.01.03110.1016/j.msec.2012.01.031 ↗
61. 10.1016/j.jcis.2009.11.06910.1016/j.jcis.2009.11.069 ↗
62.
63. 10.1016/j.jhazmat.2011.02.06110.1016/j.jhazmat.2011.02.061 ↗
64. Goswami N. · Nanoscale Adv. · 2019 · 1 · 2356
65. 10.1021/ed084p32210.1021/ed084p322 ↗
66. 10.1099/jmm.0.47146-010.1099/jmm.0.47146-0 ↗
67. 10.1128/JCM.43.11.5721-5732.200510.1128/JCM.43.11.5721-5732.2005 ↗
68. 10.1099/mic.0.027706-010.1099/mic.0.027706-0 ↗
69.
70. 10.1099/jmm.0.069609-010.1099/jmm.0.069609-0 ↗
71. 10.1002/mabi.20120005210.1002/mabi.201200052 ↗
72. 10.18231/j.ijohd.2019.02210.18231/j.ijohd.2019.022 ↗
73. 10.1111/jcpe.1338210.1111/jcpe.13382 ↗
74. 10.1016/j.heliyon.2020.e0428710.1016/j.heliyon.2020.e04287 ↗
75. 10.1002/jcp.2171010.1002/jcp.21710 ↗
76. 10.1080/00498259823936210.1080/004982598239362 ↗
77. Iso B. · Part · 2009 · 1 · 10993
78. 10.3390/polym710150310.3390/polym7101503 ↗
79.
80. 10.1016/j.tiv.2005.06.03410.1016/j.tiv.2005.06.034 ↗
81. 10.1016/j.toxlet.2008.04.01510.1016/j.toxlet.2008.04.015 ↗
82. 10.1016/j.toxlet.2009.07.00910.1016/j.toxlet.2009.07.009 ↗
83. 10.1016/j.toxlet.2011.11.00210.1016/j.toxlet.2011.11.002 ↗
84. 10.1021/jp712087m10.1021/jp712087m ↗
85.
86. 10.1016/j.coche.2011.07.00110.1016/j.coche.2011.07.001 ↗
87. 10.1007/s11356-017-9367-910.1007/s11356-017-9367-9 ↗
88. 10.1007/s00204-012-0840-410.1007/s00204-012-0840-4 ↗
89. 10.1128/IAI.36.2.576-581.198210.1128/IAI.36.2.576-581.1982 ↗
90.
91. E. C. o. A. S. Testing Version2015 5 2015;
92. I. O. f. Standardization Clinical Laboratory Testing and in Vitro Diagnostic Test Systems-Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices: Reference Method for Testing the in Vitro Activity of Antimicrobial Agents Against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases ISO 2006.
93. 10.1007/BF0209401810.1007/BF02094018 ↗